| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | fluticasone furoate/umeclidinium/vilanterol (Trelegy® Ellipta®) |
| Formulation | 92 micrograms/55 micrograms/ 22 micrograms inhalation powder |
| Reference number | 3972 |
| Indication | Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease who are not adequately treated by a combination of an inhaled long-acting β2-agonist and long-acting muscarinic receptor antagonist (for effects on symptom control and prevention of exacerbations) |
| Company | GlaxoSmithKline |
| BNF chapter | Respiratory system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 08/10/2018 |